Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Sci Rep. 2021 Mar 18;11(1):6367. doi: 10.1038/s41598-021-85449-2.
Obesity, a major healthcare problem worldwide, induces metabolic endotoxemia through the gut translocation of lipopolysaccharides (LPS), a major cell wall component of Gram-negative bacteria, causing a chronic inflammatory state. A combination of several probiotics including Lactobacillus acidophilus 5 (LA5), a potent lactic acid-producing bacterium, has previously been shown to attenuate obesity. However, data on the correlation between a single administration of LA5 versus microbiota alteration might be helpful for the probiotic adjustment. LA5 was administered daily together with a high-fat diet (HFD) for 8 weeks in mice. Furthermore, the condition media of LA5 was also tested in a hepatocyte cell-line (HepG2 cells). Accordingly, LA5 attenuated obesity in mice as demonstrated by weight reduction, regional fat accumulation, lipidemia, liver injury (liver weight, lipid compositions, and liver enzyme), gut permeability defect, endotoxemia, and serum cytokines. Unsurprisingly, LA5 improved these parameters and acidified fecal pH leads to the attenuation of fecal dysbiosis. The fecal microbiome analysis in obese mice with or without LA5 indicated; (i) decreased Bacteroidetes (Gram-negative anaerobes that predominate in non-healthy conditions), (ii) reduced total fecal Gram-negative bacterial burdens (the sources of gut LPS), (iii) enhanced Firmicutes (Gram-positive bacteria with potential benefits) and (iv) increased Verrucomycobia, especially Akkermansia muciniphila, a bacterium with the anti-obesity property. With LA5 administration, A. muciniphila in the colon were more than 2,000 folds higher than the regular diet mice as determined by 16S rRNA. Besides, LA5 produced anti-inflammatory molecules with a similar molecular weight to LPS that reduced cytokine production in LPS-activated HepG2 cells. In conclusion, LA5 attenuated obesity through (i) gut dysbiosis attenuation, partly through the promotion of A. muciniphila (probiotics with the difficulty in preparation processes), (ii) reduced endotoxemia, and (iii) possibly decreased liver injury by producing the anti-inflammatory molecules.
肥胖是全球主要的医疗保健问题,它通过脂多糖(LPS)的肠道易位诱导代谢性内毒素血症,LPS 是革兰氏阴性菌的主要细胞壁成分,导致慢性炎症状态。先前已经表明,包括产乳酸能力很强的嗜酸乳杆菌 5(LA5)在内的几种益生菌的组合可以减轻肥胖。然而,关于单次给予 LA5 与微生物群改变之间的相关性的数据可能有助于益生菌的调整。LA5 与高脂肪饮食(HFD)一起每天给予小鼠 8 周。此外,还在肝细胞系(HepG2 细胞)中测试了 LA5 的条件培养基。相应地,LA5 减轻了小鼠的肥胖,表现为体重减轻、局部脂肪堆积、血脂异常、肝损伤(肝重、脂质组成和肝酶)、肠道通透性缺陷、内毒素血症和血清细胞因子。不出所料,LA5 改善了这些参数,并且酸化粪便 pH 值导致粪便菌群失调的减轻。有或没有 LA5 的肥胖小鼠的粪便微生物组分析表明;(i)拟杆菌门减少(在非健康条件下占优势的革兰氏阴性厌氧菌),(ii)总粪便革兰氏阴性细菌负荷减少(肠道 LPS 的来源),(iii)厚壁菌门增加(具有潜在益处的革兰氏阳性细菌),(iv)韦荣球菌科增加,特别是阿克曼氏菌属,一种具有抗肥胖特性的细菌。通过 16S rRNA 测定,用 LA5 给药后,A. muciniphila 在结肠中的数量比常规饮食组的小鼠高 2000 多倍。此外,LA5 产生了与 LPS 分子量相似的抗炎分子,减少了 LPS 激活的 HepG2 细胞中细胞因子的产生。总之,LA5 通过以下方式减轻肥胖:(i)肠道菌群失调的减轻,部分是通过促进 A. muciniphila(制备过程困难的益生菌),(ii)内毒素血症的减少,和(iii)可能通过产生抗炎分子来减少肝损伤。